XORTX Therapeutics (XRTX) Total Non-Current Liabilities (2020 - 2025)
XORTX Therapeutics (XRTX) posted Total Non-Current Liabilities of $812662.0 for Q3 2025, up 18.34% on a QoQ basis from $686709.0 in Q2 2025, and down 51.97% year-over-year from $1.7 million in Q3 2024.
XORTX Therapeutics (XRTX) Total Non-Current Liabilities (2020 - 2025) Analysis & Trends
XORTX Therapeutics' Total Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $812662.0 for Q3 2025.
- Quarterly Total Non-Current Liabilities fell 51.97% year-over-year to $812662.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $812662.0 (down 51.97% YoY) and the FY2024 annual result came in at $733244.0, down 8.48% from the prior year.
- Total Non-Current Liabilities was $812662.0 for Q3 2025 at XORTX Therapeutics, up from $686709.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $9.6 million in Q3 2021 and bottomed at $378516.0 in Q2 2023.
- A 5-year average of $2.5 million and a median of $1.7 million in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities plunged 87.2% — and 2024, when it jumped 514.69%.
- XORTX Therapeutics' Total Non-Current Liabilities stood at $4.2 million in 2021, then rose by 27.92% to $5.3 million in 2022, then slumped by 85.01% to $801192.0 in 2023, then dropped by 8.48% to $733244.0 in 2024, then advanced by 10.83% to $812662.0 in 2025.
- Business Quant data shows XRTX's Total Non-Current Liabilities at $812662.0 in Q3 2025, $686709.0 in Q2 2025, and $732604.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | XORTX Therapeutics | 20.40 Mn | 20.40 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 812,662.00 |
| Jun 30, 2025 | 686,709.00 |
| Mar 31, 2025 | 732,604.00 |
| Dec 31, 2024 | 733,244.00 |
| Sep 30, 2024 | 1.69 Mn |
| Jun 30, 2024 | 2.07 Mn |
| Mar 31, 2024 | 3.53 Mn |
| Dec 31, 2023 | 801,192.00 |
| Sep 30, 2023 | 529,011.00 |
| Jun 30, 2023 | 378,516.00 |
| Mar 31, 2023 | 575,042.00 |
| Dec 31, 2022 | 5.34 Mn |
| Sep 30, 2022 | 3.24 Mn |
| Jun 30, 2022 | 2.96 Mn |
| Mar 31, 2022 | 3.95 Mn |
| Dec 31, 2021 | 4.18 Mn |
| Sep 30, 2021 | 9.56 Mn |
| Dec 31, 2020 | 768,569.60 |